Abstract:In recent years, engineering T cell therapy has made great progress in tumor immunotherapy, which mainly includes T-cell receptor-engineered T cell（TCR-T） therapy and chimeric antigen receptor T cell（CAR-T） therapy. Due to their structure difference, TCR-T and CAR-T cells show different characteristics in signal activation and antigen recognition. CAR has scFv derived from antibody, containing CD3ζ and costimulatory domain（s）, making engineered CAR able to recognize specific tumor associated antigens. Therefore, CAR has an ability to bind unprocessed tumor surface antigens without MHC processing, while TCR engages with both tumor intracellular and surface antigens embedded in MHC. While CAR-T cell therapy has demonstrated a significant clinical effect against malignant blood tumors, TCR-T cell therapies have been tested in hematological and solid tumors. Even though clinical results are encouraging for both approaches, several major challenges have been identified, including: target antigen selection such as less tumor toxicity and antigen escape, T cell homing to the tumor, T cell infiltration into the tumor, T cell persistence, and local immunosuppression in the tumor microenvironment. Synthetic biology technologies have enabled flexible reprogramming of engineered T cells to overcome the aforementioned limitations, bringing new opportunities for improving their safety and effectiveness, but the choice of a suitable target antigen is still a key for success. Moreover, improved preclinical TCR/CAR screening is likely to enhance the safety of engineered T cell therapies, and additional T cell engineering to further enhance engineered T cells at various levels has generated promising results, including:（1） modulation of affinity,（2） safety control elements, and（3） targeting TME components. Future developments will likely harness combinatorial strategies to overcome challenges posed by the tumors. In this article, we address structure and signal activation, target selection, affinity optimization, safety modification and gene editing strategies for engineered T cells, and also review the potential synthetic biological approaches and latest progress of engineered T cell therapy in the application of tumor immunotherapy.

Synthetic biology approaches for improving the specificity and efficacy of cancer immunotherapy

When Natural Compounds Meet Nanotechnology: Nature-Inspired Nanomedicines for Cancer Immunotherapy

Genetically engineered T cells for cancer immunotherapy

Synthetic Cells and Molecules in Cellular Immunotherapy

Synthetic immunology: T-cell engineering and adoptive immunotherapy

Engineering Principles for Synthetic Biology Circuits in Cancer Immunotherapy

Improving Safety of Cancer Immunotherapy Via Delivery Technology.

Improving Safety Of Cancer Immunotherapy Via Delivery Technology

Molecular and nanoengineering approaches towards activatable cancer immunotherapy.

Emerging nanotechnological strategies to reshape tumor microenvironment for enhanced therapeutic outcomes of cancer immunotherapy.

Engineered Bacteria in Tumor Immunotherapy

Nanoengineered Targeting Strategy for Cancer Immunotherapy

Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities

Chemical and Synthetic Biology Approaches for Cancer Vaccine Development

The New Progress in Cancer Immunotherapy

Synthetic biology and engineered T cell therapy

Engineered Bacteria: Strategies and Applications in Cancer Immunotherapy

Enhancing cancer immunotherapy: Nanotechnology-mediated immunotherapy overcoming immunosuppression

Biomimetic and bioinspired nano‐platforms for cancer vaccine development

Nanoparticle‐Based Nanomedicines to Promote Cancer Immunotherapy: Recent Advances and Future Directions

Bacteria−Based Synergistic Therapy in the Backdrop of Synthetic Biology